Investigational Site Number :2500002

Marseille 13885

4 studies enrolling now · 8 studies all time

What they study most

Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Amyotrophic Lateral Sclerosis, Blastic Plasmacytoid Dendritic Cell Neoplasia, Chronic Graft Versus Host Disease, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Malignant Solid Tumor, Myelodysplastic Syndromes, Neoplasm, Polyneuropathy, Inflammatory Demyelinating, Chronic

Studies at this site

• A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Recruiting now
• A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work — Recruiting now
• A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) — Recruiting now
• Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP — Enrolling by invitation
• First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) — Stopped early
• Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors — Stopped early
• Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) — Stopped early
• A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors — Completed